ORAVIG- miconazole tablet
Midatech Pharma US, Inc.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ORAVIG safely and effectively. See full prescribing information for ORAVIG.
ORAVIG (miconazole) buccal tablets
Initial U.S. Approval: January 1974
INDICATIONS AND USAGE
ORAVIG is an azole antifungal indicated for the local treatment of oropharyngeal candidiasis in adults ( 1).
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
50 mg buccal tablets ( 3)
Known hypersensitivity to miconazole, milk protein concentrate, or any other component of the product ( 4).
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions: Anaphylactic reactions have been reported in patients receiving miconazole. Discontinue ORAVIG immediately at the first sign of hypersensitivity. ( 5.1).
Most common adverse reactions (≥2%) are: diarrhea, headache, nausea, dysgeusia, upper abdominal pain, and vomiting ( 6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Fortovia Therapeutics Inc. Raleigh, NC 27615 at (855) 273-0468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding ( 7.1).
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
FULL PRESCRIBING INFORMATION: CONTENTS*
ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.
The recommended dosing schedule for ORAVIG is the application of one 50 mg buccal tablet to the upper gum region (canine fossa) once daily for 14 consecutive days.
ORAVIG should be applied in the morning, after brushing the teeth. The tablet should be applied with dry hands. The rounded side surface of the tablet should be placed against the upper gum just above the incisor tooth (canine fossa) and held in place with slight pressure over the upper lip for 30 seconds to ensure adhesion. The tablet is round on one side for comfort, but either side of the tablet can be applied to the gum.
Once applied, ORAVIG stays in position and gradually dissolves. [ See Clinical Pharmacology (12.3)] Subsequent applications of ORAVIG should be made to alternate sides of the mouth. Before applying the next tablet, the patient should clear away any remaining tablet material. In addition,
ORAVIG is a buccal tablet containing 50 mg of miconazole. ORAVIG tablets are round, off-white tablets, with a rounded side and a flat side. The tablets are marked with an "L" on the flat side.
ORAVIG is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to miconazole, milk protein concentrate, or any other component of the product.
Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including ORAVIG. Discontinue ORAVIG immediately at the first sign of hypersensitivity.
There is no information regarding cross-hypersensitivity between miconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles.
The following serious adverse drug reactions are discussed in detail in other sections of labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The overall safety of ORAVIG was assessed in 480 adult subjects: 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects.
HIV Infected Patients
Two trials were conducted in immunocompromised HIV-infected patients: one randomized, double-blind, double-dummy, active-controlled design (N = 290 ORAVIG, 287 control) and one non-comparative trial (N = 25).
In the randomized, double blind trial (Study 1), 290 HIV infected subjects used ORAVIG once daily for 14 days, and 287 subjects used 10 mg clotrimazole troches five times daily for 14 days. Adverse reactions occurring in ≥ 2% of patients in either treatment are presented in Table 1.
(MedDRA v 9.1 System Organ Class and Preferred Term)
N = 290 (%)
N = 287 (%)
|Patients with any adverse reaction during the study||158 (54.5)||146 (50.9)|
|Abdominal pain upper||1.7||2.8|
|Infections and infestations||15.9||17.1|
|Upper respiratory infection||2.1||2.4|
|Nervous system disorders||13.1||8.4|
|Blood and lymphatic disorders||6.9||8.4|
|General disorders and administration site conditions||6.6||8.0|
Overall local adverse reactions, including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritis, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain or discomfort, toothache, loss of taste, and altered taste, were reported by 35 (12.1%) patients who received miconazole buccal tablet compared to 27 (9.4%) patients who received clotrimazole troches.
Head and Neck Cancer Patients
In the randomized, open-label comparative trial of oropharyngeal candidiasis in patients with head and neck cancer who had received radiation therapy (Study 2), 147 patients used ORAVIG once daily for 14 days and 147 patients used 125 mg of miconazole oral gel four times daily for 14 days. Adverse reactions occurring in ≥2% of patients in either arm are listed in Table 2.
(MedDRA v 9.1 System Organ Class and Preferred Term)
N = 147 (%)
N = 147 (%)
|Patients with at least one adverse reaction||30 (20.4)||32 (21.8)|
|Abdominal pain, upper||1.4||2.0|
|Nervous system disorders||5.4||1.4|
|Skin and subcutaneous||3.4||0.7|
Overall local adverse reactions, including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, and application site discomfort or pain, were experienced by 14 (9.5%) patients who used ORAVIG compared to 16 (10.9%) patients who used miconazole gel.
Overall ORAVIG Safety Experience In Patients and Healthy Subjects
Adverse reactions reported in the overall safety database of 480 subjects who received miconazole buccal tablet is listed in Table 3.
(MedDRA v 9.1 System Organ Class and Preferred Term)
N = 480 (%)
|Patients with at least one AE||209 (43.5)|
|Abdominal pain upper||2.5|
|Infections and infestations||11.9|
|Nervous system disorders||10.6|
Discontinuation of ORAVIG due to adverse drug reactions occurred in 0.6% overall.
Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding.
No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out.
Based on findings from animal data, ORAVIG may cause fetal harm when administered to pregnant women. There are no available data on ORAVIG use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, prolonged gestation, dystocia and/or increased number of resorptions were observed after oral administration of miconazole nitrate during organogenesis to pregnant rats and rabbits. (See Data). Advise pregnant women of the potential risk to a fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Miconazole nitrate administered orally at doses of 80 mg/kg/day or higher to pregnant rats or rabbits crossed the placenta and resulted in embryo- and fetotoxicity, including increased fetal resorptions. These doses also resulted in prolonged gestation and dystocia in rats, but not in rabbits. Embryofetotoxicity was not observed in intravenous studies with miconazole at lower doses of 40 mg/kg/day in rats and 20 mg/kg/day in rabbits, which are approximately 8 times higher than the dose a patient would receive if she swallowed an ORAVIG buccal tablet, based on body surface area comparisons. Teratogenicity was not reported in any animal study with miconazole.
There is no available information on the presence of miconazole in human milk, or the effects on the breastfed child, or the effects on milk production following use of ORAVIG.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ORAVIG and any potential adverse effects on the breastfed infant from ORAVIG or from the underlying maternal condition.
Safety and effectiveness of ORAVIG in pediatric patients below the age of 16 years have not been established. The ability of pediatric patients to comply with the application instructions has not been evaluated. Use in younger children is not recommended due to potential risk of choking.
Clinical studies of ORAVIG did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Miconazole is metabolized by the liver. While miconazole systemic exposure is minimal following the application of ORAVIG, ORAVIG should be administered with caution in patients with hepatic impairment.
Overdose with miconazole in humans has not been reported in the literature.
Miconazole absorption and systemic exposure following application of ORAVIG are minimal [see Clinical Pharmacology (12.3)].
Symptomatic and supportive care is the basis for management.
ORAVIG (miconazole) buccal tablets are applied topically to the gum once daily and release miconazole as the buccal tablet gradually dissolves [see Clinical Pharmacology (12.3)] .
Miconazole is an imidazole antifungal agent and is described chemically as 1-[(2RS)-2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole with an empirical formula of C 18H 14Cl 4N 2O and a molecular weight of 416.13. The structural formula is shown in Figure 1.
Figure 1: Structural Formula of Miconazole
Miconazole drug substance is a white to almost white powder.
ORAVIG contains 50 mg of miconazole base, USP and the following inactive ingredients: hypromellose, USP; milk protein concentrate; corn starch, NF; lactose monohydrate, NF; sodium lauryl sulfate, NF; magnesium stearate, NF; and talc, USP.
Miconazole is an antifungal drug [see Microbiology (12.4)].
Absorption and Distribution
Single dose application of ORAVIG containing 50 mg of miconazole to the buccal mucosa of 18 healthy volunteers provided mean maximum salivary concentrations of 15 mcg/mL at 7 hours after application of the tablet. This provided an average saliva exposure to miconazole estimated from the AUC (0-24h) of 55.23 mcg∙h/mL. The pharmacokinetic parameters of miconazole in the saliva of healthy volunteers are provided in Table 4.
|Salivary PK Parameters (N = 18)||Mean ±SD
(Min - Max)
|AUC 0-24h (mcg-h/mL)||55.2 ±35.1|
|(0.5 – 128.3)|
|C max (mcg/mL)||15.1 ±16.2|
|(0.5 – 64.8)|
|T max (hour)||7 *|
|(2.0 – 24.1)|
In healthy volunteers, the duration of buccal adhesion was on average 15 hours following a single dose application of ORAVIG 50 mg.
Plasma concentrations of miconazole were below the lower limit of quantification (0.4 mcg/mL) in 157/162 (97%) samples from healthy volunteers following single-dose application of ORAVIG 50 mg. Measurable plasma concentrations ranged from 0.5 to 0.83 mcg/mL.
Plasma concentrations of miconazole evaluated after 7 days of treatment in 40 HIV-positive patients were all below the limit of quantification (0.1 mcg/mL).
Metabolism and Excretion
Most of the absorbed miconazole is metabolized by the liver with less than 1% of the administered dose found unchanged in urine. In healthy volunteers, the terminal half-life is 24 hours following systemic administration. There are no active metabolites of miconazole.
Mechanism of Action
Miconazole inhibits the enzyme cytochrome P450 14α-demethylase which leads to inhibition of ergosterol synthesis, an essential component of the fungal cell membrane. Miconazole also affects the synthesis of triglycerides and fatty acids and inhibits oxidative and peroxidative enzymes, increasing the amount of reactive oxygen species within the cell.
Miconazole is active against Candida albicans, C. parapsilosis and C. tropicalis. Correlation between minimum inhibitory concentration (MIC) results in vitro and clinical outcome has yet to be established.
In vitro studies have shown that some Candida strains that demonstrate reduced susceptibility to one antifungal azole may also exhibit reduced susceptibility to other azoles suggesting cross-resistance.
Clinically relevant resistance to systemically utilized triazoles may occur in Candida species. Resistance may occur by multiple mechanisms such as changes in amino acids and/or in the regulation of the target enzyme and of a variety of efflux pump proteins. Multiple mechanisms may co-exist in the same isolate. Resistance breakpoints, correlating in vitro activity with clinical efficacy, have not been established for miconazole.
Carcinogenicity studies with miconazole have not been conducted.
Miconazole nitrate was not genotoxic when tested in vitro in a bacterial reverse mutation (Ames) assay or in an in vivo mouse bone marrow micronucleus test. Intraperitoneal injections of miconazole to mice induced chromosomal aberrations in spermatocytes and bone marrow cells, and morphologic abnormalities in sperm at doses similar to or below clinical doses. However, no impairment of fertility was observed in intravenous studies with miconazole at 40 mg/kg/day in rats or 20 mg/kg/day in rabbits, which are approximately 8 times higher than the dose a patient would receive if she swallowed an ORAVIG buccal tablet, based on body surface area comparisons.
Study in HIV Infected Patients
The efficacy and safety of ORAVIG in the treatment of OPC was evaluated in a randomized, double-blind, double-dummy, multicenter trial comparing ORAVIG 50 mg once daily for 14 consecutive days (n = 290) with clotrimazole troches 10 mg 5 times per day for 14 days (n = 287) in HIV-positive patients with OPC. Seventy-five percent of patients were not receiving highly active antiretroviral treatment, 5% had CD4+ cell count < 50 cells/mm 3, and 17% had a history of previous OPC. The mean viral load was 117,000 copies/mL. Patients were required to have symptoms and microbiological documentation of OPC for study entry. Most of the infections were caused by C. albicans (85%), followed by C. tropicalis (9%), and C. parapsilosis (3%). About 2% of the subjects were infected with more than one Candida species.
Clinical cure [defined as a complete resolution of both signs and symptoms of OPC at the test of cure (TOC) visit (days 17-22)], and clinical relapse by days 35-38 (21-24 days after end of therapy) are presented in Table 5. Mycological cure [defined as eradication (i.e., no yeast isolates) of Candida species] at the TOC visit (days 17-22) is also reported in the table.
N=290 * (%)
N=287 * (%)
|Clinical cure †||176 (60.7%)||187 (65.2%)|
|Clinical relapse ‡|
|Yes §||48 (27.3%)||52 (27.8%)|
|No||124 (70.5%)||133 (71.1%)|
|Missing||4 (2.3%)||2 (1.1%)|
|Mycological cure||79 (27.2%)||71 (24.7%)|
Study in Head and Neck Cancer Patients
The efficacy and safety of ORAVIG 50 mg was evaluated in an open-label, randomized, multicenter trial comparing ORAVIG 50 mg once daily for 14 days to miconazole oral gel 125 mg four times daily for 14 days in head and neck cancer patients who had received radiation therapy. Most of the infections were caused by C. albicans (71%), and C. tropicalis (8%). About 7% of the subjects were infected with more than one Candida species. Success rates of treatment at day 14 [defined as a complete (complete disappearance of candidiasis lesions) or partial response (improvement by at least 2 points of the score for extent of oral lesion compared with the score at day 1) based on a blind assessment] are shown in Table 6. Also reported in Table 6 are relapse rate at day 30, and mycologic cure assessed at day 14.
N=148 * (%)
|Miconazole oral gel
N=146 * (%)
|Success rate (CR+PR) †||79 (53.4%)||69 (46.6%)|
|CR ‡||74 (50.0%)||64 (43.8%)|
|Clinical relapse §|
|Yes ¶||14 (18.9%)||8 (12.5%)|
|No||59 (79.7%)||56 (87.5%)|
|Mycological cure||66 (44.6%)||78 (53.4%)|
ORAVIG 50 mg buccal tablets are supplied as off-white tablets containing 50 mg of miconazole. ORAVIG tablets have a rounded side and a flat side. ORAVIG tablets are packaged in bottles of 14 tablets (NDC 89141-250-14).
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Important Administration Instructions
The tablet should be used immediately after removal from the bottle.
Patients should avoid situations that could interfere with the sticking of the tablet including:
Hypersensitivity and Other Adverse Reactions
Patients who develop hives, skin rash, or other symptoms of an allergic reaction, and patients who develop swelling or pain, at the tablet application site should stop ORAVIG and contact a healthcare provider. Patients may experience other adverse reactions including diarrhea, headache, nausea, and change in taste.
Potential Embryo-fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)] .
Catalent Germany Schorndorf GmbH
Fortovia Therapeutics Inc.
8540 Colonnade Center Drive, Suite 101
Raleigh, NC 27615
Address medical inquires to:
Fortovia Therapeutics Inc.
US patent numbers: 6,916,485; 7,651,698; 8,518,442.
©2020 Fortovia Therapeutics Inc.
|This Patient Information has been approved by the U.S. Food and Drug Administration||Revised: 1/2020|
|Read this Patient Information Leaflet that comes with ORAVIG before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.|
|What is ORAVIG?
|Who should not use ORAVIG?|
|Do not use ORAVIG if you are allergic to:
|What should I tell my doctor before using ORAVIG?|
|Before taking ORAVIG, tell your doctor about all of your medical conditions, including if you:
|Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.|
|ORAVIG may affect the way other medicines work, and other medicines may affect how ORAVIG works.|
|Especially tell your doctor if you take:
|Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.|
|How should I use ORAVIG?
|What should I avoid while using ORAVIG?|
|You should avoid activities that may prevent ORAVIG from sticking to your gum, including:
|What are the possible side effects of ORAVIG?|
|ORAVIG may cause serious side effects, including:|
|Allergic reactions. Stop using ORAVIG and tell your doctor right away or get emergency medical help if you have any of the symptoms below:
|Stop using ORAVIG and tell your doctor if you develop swelling or pain at the tablet application site.|
|The most common side effects of ORAVIG include:|
|Tell your doctor if you have any side effect that bothers you or that does not go away.|
|These are not all the possible side effects of ORAVIG. For more information, ask your doctor or pharmacist.|
|Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.|
|How should I store ORAVIG?
|Keep ORAVIG and all medicines out of the reach of children.|
|General information about the safe and effective use of ORAVIG.|
|Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use ORAVIG for a condition for which it was not prescribed. Do not give ORAVIG to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information Leaflet summarizes the most important information about ORAVIG. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ORAVIG that is written for health professionals. You can also visit www.oravig.com for more information.|
|What are the ingredients in ORAVIG?|
|Active ingredient: miconazole|
|Inactive ingredients: hypromellose, milk protein concentrate, corn starch, lactose monohydrate, sodium lauryl sulfate, magnesium stearate, and talc.|
|Manufactured By: Catalent Germany Schorndorf GmbH Steinbeisstraße 1-2 73614 Schorndorf Germany|
|Distributed by: Fortovia Therapeutics Inc. 8540 Colonnade Center Drive, Suite 101 Raleigh, NC 27615|
|Address medical inquires to: Fortovia Therapeutics Inc. 1-855-273-0468|
|US patent numbers: 6,916,485; 7,651,698; 8,518,442.|
|©2020 Fortovia Therapeutics US Inc.|
Read this Instructions for Use before you start using ORAVIG and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment. Talk to your doctor or pharmacist if you have any questions about how to use ORAVIG.
How should I store ORAVIG?
Keep ORAVIG and all medicines out of the reach of children.
How to use ORAVIG?
Before applying the ORAVIG tablet
Step 1. Locate the area on the upper gum, just above the left or the right incisor tooth. The incisor tooth is the tooth just to the right or left of your two front teeth (See Figure A).
Step 2. With dry hands, take 1 ORAVIG tablet out of the bottle. ORAVIG is round on one side and flat on the other side (See Figure B). The tablet is marked with an "L" on the flat side.
Applying the ORAVIG tablet
Step 3. Place the flat side of the ORAVIG tablet on your dry fingertip. Gently push the round side of the tablet against your upper gum in the area shown in Figure C. Push the ORAVIG tablet up as high as it will go on your gum. The flat side will be facing the inside of your lip.
Step 4. Hold the ORAVIG tablet in place by applying a slight pressure with your finger on the outside of your upper lip for 30 seconds (See Figure D). This will make the tablet stick to your gum.
Step 5. Leave the ORAVIG tablet in place until it dissolves. Do not remove the tablet.
Step 6. Before applying your next dose, be sure to clear away any remaining ORAVIG tablet material on your gum.
Manufactured By: Catalent Germany Schorndorf GmbH Steinbeisstraße 1-2 73614 Schorndorf Germany
Distributed by: Fortovia Therapeutics Inc. 8540 Colonnade Center Drive, Suite 101, Raleigh, NC 27615
Address medical inquires to: Fortovia Therapeutics Inc. 1-855-273-0468
US patent numbers: 6,916,485; 7,651,698; 8,518,442.
©2020 Fortovia Therapeutics Inc.
This Instructions for Use has been approved by the U.S. Food and Drug Administration
|Labeler - Midatech Pharma US, Inc. (829400415)|
|Catalent Germany Schorndorf GmbH||315732628||manufacture(89141-250)|
|Olon SpA||437723684||api manufacture(89141-250)|